Infliximab in Crohn's disease: first anniversary clinical experience.
作者： Russell D Cohen , Jennifer F Tsang , Stephen B Hanauer
DOI: 10.1016/S0002-9270(00)02156-0
关键词:
摘要: Abstract OBJECTIVE: The aim of this study is to report on the first year experience with infliximab for Crohn’s disease. METHODS: All patients receiving at our institution in release were prospectively registered. Disease activity was scored initial infusion, and 1,3,7, 12 wk. Results tabulated separately luminal (L) or fistulous (F) Steroid withdrawal adverse events tabulated. RESULTS: One hundred twenty-nine treated (81 L, 48 F). Mean number infusions/patient 2.38 3.23 F. Median time response remission 8 9 days L; 10 F, respectively. Initial infusion course rates 3 wk 65% 31% 78% 24% Rates higher if concurrently 6-mercaptopurine azathioprine improved subsequent infusions. Relapse occurred a mean 8.5 L 71% 12.2 tapering seen >90%, 54% completely off steroids after second infusion. Infusion-related reactions up patients. incidence side effects did not differ concurrent immunomodulatory therapy. CONCLUSIONS: Clinical closely parallels results controlled clinical trials, includes steroid-sparing effects.
nature.com
elsevier.com
sci-hub.se 参考文章(14)
Asher Kornbluth, Infliximab approved for use in Crohn's disease: A report on the fda gi advisory committee conference Inflammatory Bowel Diseases. ,vol. 4, pp. 328- 329 ,(1998) , 10.1002/IBD.3780040415
Hendrik M. van Dullemen, Sander J.H. van Deventer, Daan W. Hommes, Hannie A. Bijl, Jaap Jansen, Guido N.J. Tytgat, James Woody, Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology. ,vol. 109, pp. 129- 135 ,(1995) , 10.1016/0016-5085(95)90277-5
Joel W. Hay, Alan R. Hay, Inflammatory bowel disease: costs-of-illness. Journal of Clinical Gastroenterology. ,vol. 14, pp. 309- 317 ,(1992) , 10.1097/00004836-199206000-00009
Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S. Smolen, Diana Davis, John D. MacFarlane, Christian Antoni, Burkhard Leeb, Michael J. Elliott, James N. Woody, Thomas F. Schaible, Marc Feldmann, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 41, pp. 1552- 1563 ,(1998) , 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
Mary Glenn Vreeland, Stephen B. Hanauer, Russell D. Cohen, Russell V. Becker, Leanne R. Larson, Advances in the management of Crohn's disease: economic and clinical potential of infliximab Clinical Therapeutics. ,vol. 20, pp. 1009- 1028 ,(1998) , 10.1016/S0149-2918(98)80082-9
Arthur F. Kavanaugh, ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITIS Rheumatic Diseases Clinics of North America. ,vol. 24, pp. 593- 614 ,(1998) , 10.1016/S0889-857X(05)70028-4
Paul Rutgeerts, Geert D'Haens, Stephan Targan, Eric Vasiliauskas, Stephen B. Hanauer, Daniel H. Present, Lloyd Mayer, Ruud A. Van Hogezand, Tanja Braakman, Kimberly L. DeWoody, Thomas F. Schaible, Sander J.H. Van Deventer, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. ,vol. 117, pp. 761- 769 ,(1999) , 10.1016/S0016-5085(99)70332-X
M.J. Elliott, R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, J.A. Bijl, J.N. Woody, Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis The Lancet. ,vol. 344, pp. 1125- 1127 ,(1994) , 10.1016/S0140-6736(94)90632-7
Alan R. Hay, Joel W. Hay, Inflammatory Bowel Disease: Medical Cost Algorithms Journal of Clinical Gastroenterology. ,vol. 14, pp. 318- 327 ,(1992) , 10.1097/00004836-199206000-00010
Russell D. Cohen, Leanne R. Larson, Joel M. Roth, Russell V. Becker, Lisa L. Mummert, The cost of hospitalization in Crohn's disease The American Journal of Gastroenterology. ,vol. 95, pp. 524- 530 ,(2000) , 10.1111/J.1572-0241.2000.01779.X